Weight Regain After Stopping GLP-1s: What STEP 1 Extension and Real-World Data Show
The most common criticism of GLP-1 weight-loss drugs is simple: "You gain it all back when you stop." This claim is partially true, but the framing matters enormously. The STEP 1 extension data showed that approximately two-thirds of lost weight was regained within a year of stopping semaglutide. But the other third was retained — and the clinical interpretation of this finding depends on how you think about obesity as a disease.1
The STEP 1 Extension Data
In the original STEP 1 trial, patients on semaglutide 2.4mg lost an average of 14.9% of body weight at 68 weeks. The extension study followed what happened after the drug was withdrawn.1
At one year post-discontinuation, patients had regained approximately two-thirds of the weight they'd lost. Cardiometabolic improvements — in blood pressure, lipids, and glycemic markers — also partially reversed. The biological explanation is straightforward: GLP-1 agonists suppress appetite by modulating hypothalamic signaling. When the drug is removed, the signaling returns to baseline, and appetite increases.
What STEP 5 Showed About Continued Treatment
STEP 5 answered the obvious follow-up question: what happens if you stay on the drug? The answer: sustained weight loss. At 104 weeks (2 years) of continuous treatment, patients maintained approximately 15% weight loss with no evidence of regain.4
This is the same pattern seen with every chronic disease medication. Blood pressure rises when you stop antihypertensives. Blood sugar rises when you stop diabetes medication. The weight regain after GLP-1 discontinuation is not a failure of the drug — it's confirmation that obesity is a chronic condition requiring ongoing treatment.
The Clinical Framing Problem
No one says "statins don't work because cholesterol goes up when you stop taking them." Yet the weight regain critique of GLP-1s applies exactly this logic. The regain data is actually an argument for long-term GLP-1 treatment — and for developing maintenance strategies that allow dose reduction or medication switching rather than complete discontinuation.
| Strategy | Evidence | Practicality |
|---|---|---|
| Continue full-dose GLP-1 | STEP 5: sustained loss at 2 years | Highest efficacy, highest cost |
| Reduce to maintenance dose | Limited data, some trials exploring | May preserve partial benefit |
| Switch to oral GLP-1 (Foundayo/Wegovy pill) | Switching trial: 5% regain from Wegovy→Foundayo | Emerging maintenance strategy |
| Discontinue with lifestyle support | ~2/3 regain at 1 year | Most common real-world outcome |
The regain data should not be used to discourage GLP-1 treatment. It should be used to set expectations: these drugs work best as long-term therapy, and the clinical conversation should focus on sustainability — insurance coverage for ongoing treatment, dose optimization, and eventual transition strategies — rather than on whether patients can stop taking them.
SOURCES
- Wilding JPH, et al. Weight regain and cardiometabolic effects after withdrawal of semaglutide. Diabetes Obes Metab. 2022;24:1553-1564.
- Rubino D, et al. Effect of continued weekly subcutaneous semaglutide vs placebo on weight loss maintenance. JAMA. 2021;325(14):1414-1425.
- Aronne LJ, et al. Continued treatment with tirzepatide for maintenance of weight reduction. JAMA. 2024.
- Garvey WT, et al. Two-year effects of semaglutide in adults with overweight or obesity: STEP 5. Nature Medicine. 2022.